Drug intelligence / Profile preview

CGT-2201

Development stage: Phase 1
Lead developer: CGeneTech
Modality: Small Molecules

Overview

CGT-2201 is an investigational **small molecule** dual inhibitor of dipeptidyl peptidase 4 and sodium-glucose cotransporter 2 being developed by CGeneTech for **diabetes**, including **type 2 diabetes mellitus**. The program is designed to combine two established antihyperglycemic mechanisms in a single agent: DPP-4 inhibition to enhance incretin signaling and improve glucose-dependent insulin secretion, and SGLT2 inhibition to increase urinary glucose excretion. Based on the provided company pipeline and source context, CGT-2201 appears to be in **IND-stage development**.

Targets

DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on CGT-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGT-2201.